This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Karnani, P. Articles by Kairemo, K. Search for Related Content PubMed PubMed Citation Articles by Karnani, P. Articles by Kairemo, K.

Targeting Endothelial Growth with Monoclonal Antibodies against Tie-1 Kinase in Mouse Models¹

Department of Pharmacology, Institute of Biomedicine, FIN-00014 University of Helsinki, Helsinki, Finland [P. K.], and Department of Nuclear Medicine, Uppsala University Hospital, S-751 85 Uppsala, Sweden [K. K.]

Purpose: Tie-1 is a transmembrane tyrosine kinase expressed in vascular endothelial cells during angiogenic processes and vasculogenesis. Here we evaluate targeting of rebuilding endothelium with ¹²⁵I-labeled Tie-1 monoclonal antibodies (mAbs) in mice.

Experimental Design: At first, activity of Tie-1 kinase during reforming of blood vessels was evaluated in melanoma allografts in transgenic mice with 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside staining of the Tie-1 promoter gene. Subsequently, in vivo targeting of the healing wound was evaluated with iodinated Tie-1 mAbs in mice, and finally, after confirming the specificities for targeting, we evaluated the biodistribution of Tie-1 mAbs in a melanoma model.

Results: Tie-1 mAbs target epithelial skin wounds in mice. Biokinetics of ¹²⁵I-Tie-1 mAbs demonstrate a stabilized equilibrium between the blood and wound over 3 days. The accumulation in wound is 21% injected dose/gram (ID/g) and 17% ID/g at 48 h with the two clones of Tie-1 mAbs, 3c4c7 and 10f11g6. Tie-1 promoter is active in the melanoma model in mice. In melanomas, the tumor accumulation is 5% and 4.4% ID/g, and the tumor:liver values are 2.7 and 4.4, respectively, for the two clones of Tie-1 mAbs, 3c4c7 and 10f11g6. The clearance of ¹²⁵I-Tie-1 antibodies is slow when compared with that of the iodinated control antibody.

Conclusions: Targeting to wound is demonstrated with the Tie-1 mAbs. Accordingly, tumor targeting of melanoma is expertized with the same antibodies.